Active Filter(s):
Details:
Blue Water expands its commercial portfolio by purchasing six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. The assets also include Conjupri (levamlodipine), a calcium channel blocker for the hypertension.
Lead Product(s): Levoamlodipine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Conjupri
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Blue Water Vaccines
Deal Size: $8.5 million Upfront Cash: $8.5 million
Deal Type: Acquisition June 14, 2023